Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
June 8th - "Our job when it comes to partnering is to get our pipeline far enough along to present positive datasets to several potential partners and go from there. That's the point we are at currently."
"I'm also pleased to say that the encouraging data we've reported on our drug candidates have sparked sufficient interest with multiple big pharma to support continued discussions under CDA. Partnership remains a key focus as we enter the second half of 2017."
2nd half of 2017 is only 10 days away. Catalyst after catalyst after catalyst...
June 8th - "After completion of cohort C this month, we will have more updated information, and after it is reviewed, we will share the data with shareholders."
May 18th - "Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), is pleased to announce that patient enrollment has been completed in the third and final cohort of its Phase 2 open-label, Proof-of-Concept (PoC) clinical trial evaluating Brilacidin as a novel, non-corticosteroid, non-biologic treatment for mild-to-moderate Ulcerative Proctitis / Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD)."
May 10th - "This week Cellceutix anticipates enrolling the final subjects for the Brilacidin 42-day UP/UPS clinical study. "
Prurisol long-term safety data is known. Interim analysis will be on a majority of patients....
May 10th-" Between patients already enrolled and those presently in screening, Cellceutix has reached over 70 percent of the anticipated number of trial participants in its Phase 2b trial of Prurisol"
There is no point.
Let's not forget one of the most important points, it is safe! ...it is a pro-drug of an approved drug, there was a successful crossover study and results from the phase 2a to boot.
For any others like me who are watching the patent information closely, I want to draw your attention to slide 11 "ANAVEX 2-73 also shows synergistic activity with three generations of epilepsy drugs currently on the
market: ETS (Zarontin®), VPA (Depakene®) and Gabapentin (Neurontin®)"
Angelman Presentation
If AVXL is going to pursue a combo patent here, they could follow a similar process as with the Plus patent. By demonstrating SYNERGY, the FDA should allow them to patent the combinations.
They have in the past:
NEW YORK, NY, August 12, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Pat. App. No. 14/205,637 related to ANAVEX 2-73. Upon issuance, the patent will provide intellectual property (IP) protection until at least 2035. ANAVEX2-73 is the subject of an ongoing Phase 2a clinical trial for the treatment of Alzheimer’s disease.
The allowed patent claims cover formulations and treatments that provide particular coverage relating to improved sigma receptor ligands and their use.
“This patent is a valuable addition to our IP portfolio and covers innovations we have made in our development efforts for ANAVEX 2-73 and beyond,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We have filed numerous patent applications to cover promising compositions and therapies, including those pertaining to ANAVEX 2-73, in keeping with our commitment to a comprehensive IP protection strategy.”
Additional U.S. patent applications filed for pharmaceutical composition of matter for ANAVEX 2-73 will, if granted, provide further patent protection until at least 2035. An additional patent application on file for ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil, if granted, will provide protection for composition of matter until at least 2033.
The USPTO issues a Notice of Allowance after it determines that a patent should be granted for a claimed invention that is novel in comparison to all known technology in existence. Based on the timing of this Notice of Allowance, Anavex expects the patent to be issued by the end of 2015.
No problem. It's the least I can do help with the patent discussion.
ANAVEX2-73 AND CERTAIN ANTICHOLINESTERASE INHIBITORS COMPOSITION AND METHOD FOR NEUROPROTECTION
13/940,352
Allowed -- Notice of Allowance Not Yet Mailed
05-02-2017 Notice of Allowance Data Verification Completed
Leo responds to my emails. You should give it a try sometime.
Leo is fine. The only ones sweating are the speculators.
Seems pretty clear that the markets think Mako is a coward and his content in bullshit.
Absolutely. I had curtailed my expectations of getting OM results anytime before summer. Now knowing we have the 36 enrolled, we have another major catalyst to look forward too early spring. This year will be explosive.
Closed at the high of the day!
I'm glad Leo is in charge of finances for CTIX. The same baseless anonymous posts about having a funding issue have been wrong year after year after year. Go Leo!
And your reasoning tragically neglects a simple concept of expectations. Simple stuff actually, but now your making me think back to economics from undergrad. It's never too late to learn something new!
For clarification, I did send a response at one point stating that the Q1 was more of my own impression based on the response to Cabel's question of "when". Cabel asked something to the effect of "by the end of the second quarter?" and Leo's response was something like that would be more than enough time. My one regret in taking notes, was I am not 100% positive he said "Board of Directors", maybe Leo meant Scientific Advisory Board, or just another to the executive team. I know this doesn't help much, I will be more careful next time as every word has the potential to haunt the board's imagination.
COME ON CTIX SALES TEAM!!!
Make those quotas!
With a 150,000 shares, now each time CTIX is up a penny, you will make $2578! AWESOME!
So Super to get such a confidence Phrom new shareholders!
It is a shame that so much naked shorting of stock is allowed by the SEC. CTIX would benefit if there was no naked shorting allowed.
Hmmm, and to think we are in May...hmmm....and to think the clinical trial status has been changed to completed. Yup, when I read you response....ummm, let's just say I'm now wearing clean underwear...
Just for fun BK, do you have a guess as to the P results? Given the difficult trial (targeting a particular lesion!) and factoring in some 20% placebo effect, and based on preclinicals...
Are you thinking 50% met the primary endpoint (70%?)
This stock sux.
It just keeps going up every single day!
Sorry to disappoint, but the stock is up again.
This is incorrect. I use Scottrade and the streamer has been working fine all day.
Everyday CTIX keeps inching further along. All eyes await the P data. Tick tock tick tock....greeen!
Locked and loaded. CTIX news will be coming fast, furious and large. I don't want to get burned by being out. I'm SPF 100 safe.
I like the sound of that! Seems burglars don't like no barking dogs!
The CTIX fuse is lit. Can't wait till Kaboom! We should all get together for a celebration party. I think the first stage will be P results! We can party all night till the sun sets!
Don't forget Leo brought on Trust late last year:
https://finance.yahoo.com/news/cellceutix-retains-former-durata-executive-123000164.html
I was pleasantly surprised to see that too. EFFICACY here we come!
I don't know if this has already been noted, but K trial status is back to Active, not recruiting.
https://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=4
The Hound is my hero.
TD - I don't have my notes here but if I recall correctly, it is a CTIX paper that has lots of DF input. Menon stated that the K paper has been submitted. The typical process is to get comments back from the reviewers. At this point, they are waiting for the comments.